![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation
|
|
|
Reported by Jules Levin
David E. Martin, PharmD*
Tobira Therapeutics, Inc.
*On behalf of TBR-652-2-201 Study Team
XVIII International AIDS Conference, Vienna, Austria 20 July 2010
![](../images/071910/071910-8/image002.gif)
![](../images/071910/071910-8/image004.gif)
![](../images/071910/071910-8/image006.gif)
![](../images/071910/071910-8/image008.gif)
![](../images/071910/071910-8/image010.gif)
![](../images/071910/071910-8/image012.gif)
![](../images/071910/071910-8/image014.gif)
![](../images/071910/071910-8/image016.gif)
![](../images/071910/071910-8/image018.gif)
![](../images/071910/071910-8/image020.gif)
![](../images/071910/071910-8/image022.gif)
![](../images/071910/071910-8/image024.gif)
![](../images/071910/071910-8/image026.gif)
![](../images/071910/071910-8/image028.gif)
![](../images/071910/071910-8/image030.gif)
![](../images/071910/071910-8/image032.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|